SK biopharmaceuticalsSK바이오팜
326030 · KOSPI · ₩326030 · SK바이오팜
₩77,800▲ ₩2,600 (3.46%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 94.0% | 93.9% | 92.1% | 90.4% | 84.7% | 94.7% |
| Operating margin | 35.2% | 28.9% | 17.6% | −10.6% | −53.2% | 22.7% |
| Net margin | 46.6% | 37.8% | 44.0% | −10.0% | −56.6% | 15.5% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +21.9% | +29.1% | +54.3% | +44.2% | −41.2% | — |
| Operating income growth | +48.7% | +111.7% | +356.8% | +71.4% | −238.0% | — |
| Net income growth | +50.2% | +10.9% | +780.4% | +74.6% | −315.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 43.7% | 39.3% | 58.0% | −11.8% | −36.7% | 14.6% |
| Return on assets | 23.6% | 22.7% | 25.8% | −5.1% | −21.3% | 10.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 38.9% | 45.0% | 80.6% | 125.3% | 109.8% | 44.9% |
| Net debt to equity | — | −37.5% | −30.3% | −30.1% | 12.5% | — |
| Current ratio | 271.6% | 231.4% | 164.4% | 202.3% | 299.2% | 317.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: SK biopharmaceuticals / SK바이오팜 / 326030 / KRX:326030
Source: KRX statistical information